timolol maleate + dorzolamide hydrochloride contact lens

This is an investigational drug-eluting contact lens system developed by the University of Florida for the treatment of glaucoma. The system is loaded with two active pharmaceutical ingredients: timolol maleate, a non-selective beta-adrenergic receptor blocking agent, and dorzolamide hydrochloride, a carbonic anhydrase inhibitor. The technology utilizes vitamin E nano-barriers within the lens matrix to create a tortuous path for drug molecules, thereby extending the release duration to approximately two days and significantly increasing bioavailability compared to traditional eye drops. In preclinical models, the lenses demonstrated sustained intraocular pressure (IOP) reduction for up to nine days post-removal with a six-fold lower drug load than conventional formulations. The platform was evaluated in a Phase 1 clinical trial at the University of Florida and has been associated with commercialization efforts by Diopter Corp.

Other names

vitamin E-enhanced drug-eluting contact lensestimolol and dorzolamide loaded contact lensesUF drug-eluting contact lens